• Infectious Diseases


    As the official educational partner for the Mycoses Study Group Education & Research Consortium (MSGERC), Terranova Medica has been successful in developing educational offerings since 2010. Terranova has recently developed an update to the Antifungal Toolkit that includes a review of SUBA-itraconazole and a live and enduring activity from IDWeek 2018 on invasive mold infections. We are now exploring internationally focused educational initiatives.

    Terranova has also collaborated on educational efforts to address sexual health, HIV risk, and HIV prevention in the primary care setting. In April 2017, our collaboration delivered a live meeting at the Colorado Academy of Family Physicians (CAFP) Summit on these topics, following by enduring activities with regionally customized content for use across the state of Colorado. We also created a CME activity that appeared in the Winter 2018 issue of Colorado Family Physician. And through our collaboration with the Colorado Health Network, the CAFP, and Postgraduate Institute for Medicine, we addressed patient support services and links to care in this grass-roots effort. With the patient-level outcomes achieved in this activity, we were pleased to reach Level 6 outcomes and improve patient health literacy.

    Visit to learn more.


    Lisa Tushla, PhD, H(ASCP), completed her doctoral work and postdoctoral work focusing on important topics in infectious diseases—from the role of the neutrophil in mediating the response to endotoxemia to the role of defensins in mediating colonization vs infection of leg ulcer fluids. Subsequently, Lisa worked on various infectious disease projects in the areas of otitis media, intra-abdominal infections, skin surface infections, and fungal infections. Her special interest in fungal infections can be attributed to her long-standing collaborations with the MSG since 2005, when she helped launch the Front-Line Fungus project with Peter Pappas, MD.


    I am honored to participate in the educational efforts of the MSGERC with Terranova Medica, LLC. The activity I chaired at IDWeek 2018 was very well done, and the enduring is packed full of knowledge and does justice to the dynamite material from the speakers.

    Beyond that, I appreciate Terranova’s expertise in supporting the MSGERC’s efforts to reach out to Latin America and Asia. We have extensive experience with invasive fungal infections and antifungal therapies, and with educational and advocacy programs, we would like to help these areas with their management of these serious infections through educational means and organization of experts. Fungal infections are tough, but with partners to help we can all meet the challenges of these tough infections.

    John Perfect, MD
    President, Mycoses Study Group Education & Research Consortium
    President, International Society for Human and Animal Mycology

    The Colorado Health Network is excited to provide our patients with referrals to medical providers who are knowledgeable about HIV prevention and care. We have the tools to help your patients access and pay for prevention medications that work in stopping the spread of HIV. Please visit to find out more about how we can work together to end this epidemic.

    Jessica Kobylinski
    Program Quality Officer, Colorado Health Network, Inc.

    Can we see additional updates and content on prevention of [fungal] transmissions in ICUs, ONC, transplant units?

    Participant in the 2018 IDWeek fungal symposium

    Thanks for the excellent program!

    Participants in the 2017 Fungal Frontiers enduring activity

  • Immuno-oncology (pan-tumor)


    In 2018, we launched the Immuno-Oncology (IO) Essentials Initiative at Based on requests to customize the Melanoma Nursing Initiative materials for use in the pan-tumor setting, the Immuno-Oncology (IO) Essentials Initiative was created. The faculty is a group of advanced practice providers and other members of the healthcare community who have extensive knowledge about both cancer immunotherapies and the specific tumor types for which they are approved. This effort is designed to (1) educate and engage healthcare providers to optimally address irAEs, with a focus on contextual issues within the tumor types; and (2) educate patients receiving cancer immunotherapy to be proactive members of the oncology team in terms of irAE recognition and management.

    Since its launch in late 2018, the activity has reached over 4000 HCPs across its website and social media platforms. With content searchable by tumor type, HCP materials, patient materials and video segments on side-effect management, the IO Essentials initiative has been well received throughout the world. Its innovation was recognized at a poster at the 2019 ASCO-SITC meeting. Recently, we have developed a JADPRO supplement on the IO Essentials materials and are in the process of an international expansion of the initiative with translations and audience generation to key regions internationally.


    Terranova’s founder and president, Lisa A. Tushla, PhD (formerly Faltyn), founded PharmAdura, LLC (now Paradigm Medical Communications) in 2003 and was instrumental in taking the company through the accreditation process. She is the recipient of 2 Alliance for Continuing Education in the Health Professions awards for outstanding activities, 1 in melanoma and the other in multiple myeloma. Lisa’s experience in oncology, solidified at QuestMedEd, an arm of P4 Healthcare, spans across tumor types, with a particular expertise in genitourinary cancer, hematologic malignancy, and GI cancer.


    For the IO Essentials Initiative, we brought together a group of 10 faculty who have expertise in each of these tumor types, looked at the materials created for the MNI, and then tailored that content for the specific tumor types. Our team is so excited to have this comprehensive range of resources available for oncology providers.

    Brianna Hoffner, MSN, AOCNP, RN
    Chair, IO Essentials Initiative

    The I-O Essentials is a fabulous educational resource for healthcare providers as well as patients.

    Marianne Davies DNP, ACNP, AOCNP
    IO Essentials lung cancer expert

    The Immuno-Oncology Essentials is a great resource to help guide my approach to management of immune-related adverse effects. It is also indispensable for me to have a forum where I can discuss challenging cases with other clinicians and learn from their experience!

    Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
    IO Essentials hematology/oncology expert

  • Melanoma


    One of our proudest accomplishments in our long-standing collaboration with AIM at Melanoma is the establishment of the Melanoma Nursing Initiative (MNI), a comprehensive resource about immunotherapies and targeted therapies created for oncology nurses and advance practice providers to assist them in providing optimal outcomes for their patients with melanoma. The initiative was developed to meet several goals—the most pressing being the need to improve the early recognition and management of the side effects associated with newer melanoma therapies, particularly in the community setting. The initiative’s website,, serves as a 1-stop shop for all MNI materials. It houses the MNI consensus statements (featuring care step pathways) as published in a recent 7-article supplement to the Clinical Journal of Oncology Nursing (CJON).

    The MNI site also contains comprehensive nurse toolkits on newer melanoma therapies for use in the in-practice setting as well as customizable companion patient resources, with key information on dosing, administration, side effects, and educational and financial resources. The side-effect search functionality enables healthcare providers to search for side-effect management strategies via text-based searches supporting both telephone triage and in-office assessments.  News feeds also help the learner keep up with the recent advances in melanoma management. Finally, the Q/A portal provides an expert-led discussion board for real-time exchange among professionals regarding day-to-day issues encountered in the clinic. The content is available for both online viewing and download/print across a range of devices.

    A CME activity based on the MNI materials, Melanoma Therapeutics and Side-Effect Management: Making a Difference from the Outset reached approximately 5000 learners, including over 1277 physicians. Addressing the range of therapeutics used in melanoma, the activity consistently showed an educational impact pretest to postest on this case-based activity. Visit to learn more.

    To date, the MNI initiative has reached over 15,000 learners in 127 countries and 49 states. The content has been translated into 39 languages. The demand for the MNI materials was so great across tumor types that it led to the development of the IO Essentials Initiative. Updates are planned for the MNI site, including additional information on decision-making in adjuvant therapy as well as other continuing education activities.


    Lisa A. Tushla, PhD, H(ASCP), has a deep history in melanoma. In her postdoctoral work at the University of Pennsylvania, she worked in collaboration with her late husband, dermatologist William P. Carey, Jr, MD, and Tom Kieber-Emmons, PhD, on melanoma clinical and animal models. With the launch of PharmAdura, LLC in 2003 (now Paradigm Medical Communications), Lisa drew on her relationships and knowledge in the field to help secure the Melanoma Care Coalition project, still ongoing at Paradigm, which also helped her attain a 2007 Alliance for CME Award for outstanding collaboration. In recent years, Lisa has dived back deep in the field of melanoma and is looking forward to expanding the collaborations to the CME arena.


    Please continue [this education]. It’s excellent.

    Participant in the melanoma CME/CE on

    I have been working with Terranova on melanoma projects for several years. Put simply, they “get it”– whether it’s the science, the clinical gap, or the unmet educational need for patients and clinicians. Beyond that, they have long-term and strong relationships with many of their melanoma experts, which means their collaborations go smoothly and productively.

    Today, we are seeing a large shift in the management of melanoma—more than 80% of patients are being treated in the community setting, by clinical teams who manage a variety of tumors and may see relatively few melanoma cases. Added to that is the challenge of identifying and treating the side effects of the newer melanoma therapies, many of which are unique, immune-mediated, and very different from those seen with chemotherapy. As a result, there is a huge unmet educational need for clear, concise, and easy-to-access education for these busy community-based professionals.

    I look forward to continuing to work with Terranova on future medical education and patient education projects!

    Valerie Guild, MBA, MS
    President, AIM at Melanoma Foundation

    The emergence of immunotherapy (specifically the checkpoint inhibitors) as a mainstay treatment for advanced melanoma highlights the importance of nursing involvement in the care of patients on these therapies. Never before has the field witnessed such a rapidly evolving and dramatic paradigm shift in the availability of effective therapies for so many patients. While oncology nurses are thought of as experts in these areas, the toxicity associated with checkpoint inhibitors and the associated management strategies vastly differ from traditional chemotherapy.  The MNI faculty have a wealth of experience using these regimens and are in the best position to provide the expert guidance on their optimal use. That is the idea of the initiative—to empower our nursing colleagues in the community with the necessary information and tools to provide the best care possible for patients receiving immunotherapy.

    Krista Rubin, MS, FNP-BC
    Nurse Practitioner, Center for Melanoma, Massachusetts General Hospital Cancer Center

  • Multiple Sclerosis


    Recently, Terranova has strengthened its collaboration with the Consortium of Multiple Sclerosis Centers (CMSC) in the area of multiple sclerosis education. We have already secured partial funding of our second grant with the CMSC, and we look forward to taking the learnings from our recent efforts in HCP/patient education to enhance MS education!

    Terranova is a founding member of the MS Educational Alliance, a collaborative medical education partnership that has delivered several MS related activities in recent years. Members of the Terranova team have been involved with the following MS activities:

    • Timing is Everything: The Importance of Early Intervention in Multiple Sclerosis (QuestMedEd e-based Curriculum, 2008)
    • Sound Strategies for Multiple Sclerosis: The Longer-Term Perspective (QuestMedEd e-based Curriculum, 2009)
    • MS Management: The Immunosuppressive Debate (MS Educational Alliance, Enduring debate and case-based activity with DVD,  2010)
    • Troubles and Triumphs in MS Diagnosis (MS Educational Alliance, video/DVD online, 2010)
    • When Your MS Patient Gets Sick (MS Educational Alliance, DVD/Enduring activity, 2011)
    • Lessons Learned from Challenging Cases (MS Educational Alliance, Enduring case-based activity, 2013, ongoing) Available at

    In addition, Terranova staff have worked with the Annenberg Center for Health Sciences (ACHS) on several MS related activities.


    Terranova Medica, LLC staff members have been active in many areas of neurology continuing education, including Alzheimer’s disease, cognitive aging, cervical dystonia, narcolepsy, sleep, and particularly, MS. UNMC CCE works closely with the course chair, Lisa A. Tushla, PhD, H(ASCP), of Terranova, a biomedical scientist who has been working on neurology educational initiatives for over 15 years. Terranova’s program director, Tom Davis, has expertise in the program management and development of MS education for over 5 years. Terranova has worked with an experienced medical writer who has extensive training in neurology.


    I could not agree more about the importance of emphasizing patient education and patient empowerment as part of healthcare provider education in MS. Providers need to be able to discuss the disease and how the drugs work in simple language that patients can understand. Clinic appointments can be stressful and overwhelming. Sending the patient home with patient-friendly handouts that can be read at home and shared with family is a great way to help ensure that patients have the tools they need to fully participate in the decision-making process and the care plan.

    Kirk Munsch
    Patient Advocacy Manager, Rare Patient Voice